Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitex agnus-castus fruit extract, commonly known as chasteberry, is a herbal medicine used primarily for the treatment of gynecological conditions. Its therapeutic effects are largely attributed to its dopaminergic activity; specifically, it contains diterpenes that act as agonists at the dopamine D2 receptors in the anterior pituitary. This action suppresses the secretion of prolactin, which is often elevated in women with premenstrual syndrome (PMS) and cyclic mastodynia. By lowering prolactin levels, the extract helps normalize the luteal phase of the menstrual cycle and alleviate breast pain. Beyond its established use in PMS, the extract is being investigated for its ability to reduce mammographic breast density, potentially serving as an adjunct in breast cancer screening to improve diagnostic clarity. Key pharmaceutical developers include Bionorica, which markets the extract under the brand Agnucaston and as a component of the combination product Mastodynon.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitex agnus-castus fruit extract.